Mutant KRAS promotes malignant pleural effusion formation.
about
RAS oncogenes direct metastasis.The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1.High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.Q58714389
P2860
Mutant KRAS promotes malignant pleural effusion formation.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Mutant KRAS promotes malignant pleural effusion formation.
@ast
Mutant KRAS promotes malignant pleural effusion formation.
@en
type
label
Mutant KRAS promotes malignant pleural effusion formation.
@ast
Mutant KRAS promotes malignant pleural effusion formation.
@en
prefLabel
Mutant KRAS promotes malignant pleural effusion formation.
@ast
Mutant KRAS promotes malignant pleural effusion formation.
@en
P2093
P2860
P50
P356
P1476
Mutant KRAS promotes malignant pleural effusion formation.
@en
P2093
Anastasios D Giannou
Andreas Papadakis
Antonia Marazioti
Apostolos Voulgaridis
Danai Kati
Dimitra E Zazara
Dimitrios Kardamakis
Eirini Nikolouli
Ioannis Lilis
Ioannis Psallidas
P2860
P2888
P356
10.1038/NCOMMS15205
P407
P577
2017-05-16T00:00:00Z
P6179
1085419487